FDA GLP-1 NAION Warning Prompts Label Updates
FDA GLP-1 NAION warning requires U.S. label updates after a pooled review found a numerical imbalance and could prompt prescribing caution for makers.
KEY TAKEAWAYS
- FDA required U.S. label updates after a pooled review found a numerical imbalance in rare NAION cases.
- Pooled trials tallied 15 probable NAION events, with incidence about 6.4 versus 3.8 cases per 100,000 patient-years.
- FDA advised ophthalmologic evaluation for sudden visual symptoms and to consider stopping GLP-1 RAs if NAION suspected.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
The Food and Drug Administration on Nov. 9, 2026 required makers of marketed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to add a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION) to U.S. labels after a pooled review showed a numerical imbalance in rare optic-nerve events.
Pooled Trial Findings and Risk Assessment
The FDA’s pooled review of 126 randomized controlled trials identified 15 probable NAION cases, with 10 occurring in patients treated with GLP-1 receptor agonists and five in placebo or comparator groups. The agency estimated incidence rates of about 6.4 cases per 100,000 patient-years among GLP-1 users versus 3.8 cases per 100,000 patient-years in comparison groups.
The FDA integrated clinical-trial data, animal studies, post-marketing evidence, observational research, and case reports in its assessment. It described a potential increased risk of rare NAION events but noted that an underlying causal mechanism was not established. Reported patient-level risk factors include diabetes, smoking, high blood pressure, sleep apnea, anemia, and kidney disease.
Labeling Changes and Clinical Guidance
The FDA required all application holders for marketed GLP-1 RAs to add information about the potential NAION risk to the "Warnings and Precautions" section of U.S. prescribing information. The agency did not mandate a boxed warning. The affected products include Novo Nordisk’s semaglutide medicines Ozempic and Wegovy, Eli Lilly’s tirzepatide medicines Mounjaro and Zepbound, and other marketed GLP-1 RAs such as Byetta, Victoza, Trulicity, Saxenda, Xultophy, Soliqua, Rybelsus, and Foundayo. Semaglutide labels in Europe added NAION language in June, with similar warnings already present in the United Kingdom, the European Union, Denmark, and Australia.
The FDA advised patients to seek immediate medical attention for sudden, painless vision loss, blurred or missing portions of the visual field, color distortion, or reduced central sharpness. Suspected NAION should prompt urgent ophthalmologic evaluation. Clinicians were instructed to consider discontinuing the GLP-1 receptor agonist in patients who develop NAION unless the benefits clearly outweigh the risks.
By placing this safety signal in prescribing information and issuing symptom-driven clinical guidance, the FDA’s action may influence prescribing patterns and risk management for leading GLP-1 RA products.
